Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.55 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805007 | 1.00 | CES1 (0.62) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL12804862 | 0.87 | LRRK2 (0.67) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL12804858 | 0.87 | LRRK2 (0.67) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL12938093 | 0.84 | LRRK2 (0.63) | LRRK2CA1CA2MAP3K7TAB1 | |
| SCHEMBL9472806 | 0.82 | CES1 (0.67) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL9472812 | 0.82 | CES1 (0.67) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL5740125 | 0.82 | CA1 (0.67) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL31491981 | 0.82 | CES1 (0.55) | CES1LRRK2CA1CA2MAP3K7 | |
| SCHEMBL12805384 | 0.77 | LRRK2 (0.62) | LRRK2CA1CA2MAP3K7TAB1 | |
| SCHEMBL12805383 | 0.77 | LRRK2 (0.62) | LRRK2CA1CA2MAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508512-B1 | Novel N,N'-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells | UNIV KING SAUD (SA) | 2013-07-31 | — | — | EP | disclosed |
| US-8497296-B2 | N,N′-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells | KING SAUD UNIVERSITY (SA) | 2013-07-30 | — | — | US | disclosed |
| US-8497296-B2 | N,N′-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells | KING SAUD UNIVERSITY (SA) | 2013-07-30 | — | — | US | disclosed |
| US-8497296-B2 | N,N′-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells | KING SAUD UNIVERSITY (SA) | 2013-07-30 | — | — | US | disclosed |
| EP-2508512-A1 | Novel N,N'-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells | King Saud University (SA) | 2012-10-10 | — | — | EP | disclosed |
| US-20120252860-A1 | Novel N, N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells | KING SAUD UNIVERSITY (SA) | 2012-10-04 | — | — | US | disclosed |
| US-20120252860-A1 | Novel N, N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells | KING SAUD UNIVERSITY (SA) | 2012-10-04 | — | — | US | disclosed |
| US-20120252860-A1 | Novel N, N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells | KING SAUD UNIVERSITY (SA) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252860-A1 | Novel N, N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells | ABCC1, ABCC3, ABCF1 | CES1 1308/4885LRRK2 3240/4885CA1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.